Get the Stockscreener App
80.82
0.16%
-0.13
Pre-market:
80.51
-0.31
-0.38%
Dexcom Inc stock is traded at $80.82, with a volume of 2.93M.
It is down -0.16% in the last 24 hours and down -3.66% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$80.95
Open:
$80.93
24h Volume:
2.93M
Relative Volume:
0.87
Market Cap:
$31.69B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
56.12
EPS:
1.44
Net Cash Flow:
$570.80M
1W Performance:
+3.82%
1M Performance:
-3.66%
6M Performance:
-10.73%
1Y Performance:
+8.27%
1-Day Range:
$80.32
$81.74
1-Week Range:
$78.14
$82.04
52-Week Range:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
80.82 | 31.74B | 4.30B | 571.50M | 570.80M | 1.44 |
|
ABT
Abbott Laboratories
|
130.27 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.05 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.61 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.30 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom Inc. Facing Inflection Point in Trend AnalysisTake Profit & Daily Oversold Bounce Ideas - newsimpact.co.kr
Will DexCom Inc. Hold Gains Into Close2025 Bull vs Bear & Intraday High Probability Setup Alerts - newsyoung.net
DexCom Stock: Is DXCM Underperforming the Health Care Sector? - MSN
Stock Analysis | Dexcom OutlookMixed Technicals, Strong Fundamentals, and Diverging Analyst Sentiment - AInvest
Why DexCom Inc. (DXCM) Soared Last Week - MSN
Comparing DexCom Inc. in custom built stock radarsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
Live market analysis of DexCom Inc.Global Markets & Risk Managed Investment Signals - Newser
Should you wait for a breakout in DexCom Inc.Earnings Performance Report & Weekly Momentum Stock Picks - Newser
2 Stocks to Buy on the Dip and Hold for 10 Years - The Motley Fool
Can trapped investors hope for a rebound in DexCom Inc.Weekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
Real time social sentiment graph for DexCom Inc.Portfolio Growth Summary & Real-Time Chart Pattern Alerts - Newser
Will DexCom Inc. benefit from government policySwing Trade & Free Daily Entry Point Trade Alerts - thegnnews.com
Short interest data insights for DexCom Inc.Market Sentiment Report & Real-Time Volume Analysis - Newser
What makes DexCom Inc. stock price move sharplyJuly 2025 Trends & Community Verified Swing Trade Signals - thegnnews.com
Is Weakness In DexCom, Inc. (NASDAQ:DXCM) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects? - 富途牛牛
DexCom Stock: Analyst Estimates & Ratings - Barchart.com
3 Reasons We’re Fans of DexCom (DXCM) - Yahoo Finance
FriskaAi Integrates with Dexcom’s CGM Data for AI-Powered Diabetes Management - HIT Consultant
FriskaAi and Dexcom Collaborate on CGM Data Integration for Enhanced Diabetes Management - AInvest
FriskaAi and Dexcom Enter CGM Data Integration Agreement - The Joplin Globe
Saudi Arabia Blood Glucose Device Market Trends and Company - GlobeNewswire
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
5 Revealing Analyst Questions From DexCom’s Q2 Earnings Call - Yahoo Finance
DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook - ca.finance.yahoo.com
How much upside does DexCom Inc. haveFree Investment Webinars - thegnnews.com
What’s next for DexCom Inc. stock priceMarket Stability and Long-Term Growth Outlook - Newser
Dexcom Shares Drop 1.28% on 0.33B in Volume Ranking 313th as Institutions Cut Holdings Despite Earnings Surge - AInvest
DexCom Inc. Recovery Likely Here’s What Data ShowsEntry Alert Based on Volume Spikes Detected - metal.it
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - MedTech Dive
Dexcom and Apple Watch team up to 'empower Aussies living with diabetes' - iTWire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Inside Dexcom’s strategy to stay ahead in the $13.6bn CGM market - Yahoo Finance
Dexcom Rises 1.25% on Strong Earnings Amid Leadership Shift $370M Trading Volume Ranks 315th - AInvest
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
DexCom (DXCM) Extends Losses on Day 5 Amid Leadership Change - MSN
DexCom Extends Losses Amid Leadership Change Amid Q2 Revenue Growth - AInvest
Diabetes Management App Market Is Booming So Rapidly: Dexcom, Glooko, AgaMatrix - openPR.com
Dexcom, Inc. shares rise 1.22% premarket as equity markets rebound on Fed rate cut bets. - AInvest
Avantax Advisory Services Inc. Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM) - Defense World
Global Diabetes Management Software Market Outlook 2022 - openPR.com
Day 5 of Loss Streak for DexCom Stock with -15% Return (vs. -2% YTD) [8/4/2025] - Trefis
Dexcom recall triggered by reports of speaker malfunctions - BioWorld MedTech
DexCom, Inc. (DXCM) Stock Analysis: Impressive 28.76% Upside With Strong Buy Ratings - DirectorsTalk Interviews
What are analysts’ price targets for DexCom Inc. in the next 12 monthsCapitalize on stocks with high profit margins - Jammu Links News
How volatile is DexCom Inc. stock compared to the marketCapitalize on high-yield stock opportunities - Jammu Links News
Is it the right time to buy DexCom Inc. stockCapitalize on emerging market sectors - Jammu Links News
Is DexCom Inc. stock overvalued or undervaluedExceptional portfolio growth - Jammu Links News
What analysts say about DexCom Inc. stockTriple-digit returns - Jammu Links News
What institutional investors are buying DexCom Inc. stockOverwhelming financial success - Jammu Links News
Is It Time to Buy DexCom at a Discount Before Growth Fully Materializes? - AInvest
DexCom Inc. Stock Analysis and ForecastOverwhelming profit margins - Jammu Links News
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):